SEATTLE--(BUSINESS WIRE)--Nativis Inc., a clinical stage, bio-electronic life science company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, announced the appointment of Dr. Donna Morgan Murray as Chief Regulatory Officer, effective immediately.
Murray is a seasoned healthcare professional, author of more than 60 publications in peer-referenced journals, and has served on the board of non-profits and other organizations. Most recently the Head of Global Quality & Regulatory Compliance at Bristol-Myers Squibb, Murray has held that role since 2014. Prior to that, she was the President of ZymoGenetics Inc., a biotechnology company that discovers, develops, and manufactures protein therapeutics at Bristol-Myers Squibb. Over the past 20 years, Murray has led and directed regulatory strategy and operations for Bristol-Myers Squibb, CuraGen Corporation, and Procter & Gamble Pharmaceuticals. Murray began her professional career in 1984 as a staff scientist in the Anti-Infective Research Department with Norwich Eaton Pharmaceuticals, Inc., a Procter & Gamble Company.
Murray holds a PhD in Immunology from The University of Texas Health Science Center at Houston, where she conducted research in infectious disease & clinical microbiology. Outside of her professional work, she serves as an officer and member of the board of K9 Crime Stoppers Inc. and was the Chief Operating Officer for Independence Guide Dogs.
“We are very excited to welcome Dr. Donna Morgan Murray as Chief Regulatory Officer to Nativis,” stated Chris Rivera, Chief Executive Officer of Nativis. “Dr. Murray’s extensive professional accomplishments and medical background will provide Nativis with a broad range of experience in worldwide regulatory policy, feasibility and strategy. As we develop our technology for the treatment of cancer and other serious diseases, it is critical to consider the regulatory pathway for the Voyager system and develop a comprehensive strategy that will bring us towards regulatory approval.”
Murray added, “I am very pleased to join Nativis as the Chief Regulatory Officer and look forward to applying my experience in the biopharmaceutical industry toward developing a strong regulatory strategy for the Company’s ulRFE™ technology. I look forward to working to ensure that Nativis is well prepared to meet regulatory requirements and milestones for its unique technology platform and to streamline the regulatory process and help rapidly move forward with the Voyager system.”
About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.